Pharmacy In England: Proposals For Legislative Change - National Pharmacy Association Response
The NPA has submitted its response to this consultation, commenting on the five key proposals. John Turk, NPA Chief Executive, commented: "Overall, we believe that any legislative changes to underpin the Pharmacy in England White Paper must balance stability with opportunity, while minimising administrative burdens on contractors." A summary of the NPA recommendations follows and the full response can be downloaded from
Source: www.medicalnewstoday.com

DIA's 8th Middle East Regulatory Conference To Focus On Improved Access To Medicines And Therapies
The Drug Information Association (DIA), the premier, multidisciplinary, non-profit association that provides a neutral forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes, will host the 8th Middle East Regulatory Conference (20-21 January 2009; Manama, Bahrain).
Source: www.medicalnewstoday.com

Pharmacoeconomic Guidelines In Belgium: Towards More Transparency And Consistency
Belgian policy makers increasingly pay attention to a drugs' value for money when deciding on the reimbursement of a drug. The current guidelines aim to increase the transparency and consistency of pharmacoeconomic analyses submitted as part of a drug reimbursement request in Belgium. Before a drug is reimbursed, the pharmaceutical company has to submit a pharmacoeconomic evaluation to the Drug Reimbursement Committee (DRC).
Source: www.medicalnewstoday.com

Neuromed Completes Enrollment For Phase 3 Chronic Low Back Pain Clinical Trial Of NMED-1077
Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, announced it has completed enrollment in the pivotal Phase 3 chronic low back pain clinical trial of NMED-1077 (OROS(R) Hydromorphone) for the treatment of chronic moderate-to-severe pain in opioid tolerant patients.
Source: www.medicalnewstoday.com

Amgen, Takeda And Millennium Provide Update On Phase 3 Trial Of Motesanib In Patients With Non Small Cell Lung Cancer
Amgen (Nasdaq: AMGN) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC).
Source: www.medicalnewstoday.com

Vienna To Host BIO-Europe 2009 - First Time Event Is Held Outside Of Germany
At the closing of BIO-Europe 2008 in Mannheim/Heidelberg which saw 2400 life science executives engage in an astounding 10,250 one-to-one meetings, EBD Group today announced that next year's BIO-Europe partnering conference will pay a visit to Vienna, Austria. The 15th annual edition of BIO-Europe, the world's largest stand-alone partnering event will gather leaders of the life science industry at the Wiener Messe on Nov. 2-4, 2009 to take dealmaking to a new level.
Source: www.medicalnewstoday.com

White Paper Outlines Roles For Pharmacists In Assisting Patients AndTheir Families Dealing With Alzheimer's Disease
The November/December issue of the Journal of the American Pharmacists Association (JAPhA) features an article titled: White paper on expanding the role of pharmacists in caring for individuals with Alzheimer's disease. The white paper presents a summary discussion from a meeting held on March 5-6, 2008 convened by the American Pharmacists Association (APhA) Foundation.
Source: www.medicalnewstoday.com

European Agency For The Evaluation Of Medicinal Products Recommends Suspension Of Marketing Authorisation For IONSYS(R)
Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended suspension of the marketing authorisation for IONSYS(R) (fentanyl iontophoretic transdermal system), indicated for the management of acute moderate to severe post-operative pain for use in a hospital setting only.
Source: www.medicalnewstoday.com

More Than 2,000 New Medicines In Development For Older Americans
More than 2,000 medicines for older Americans are currently being tested in clinical trials or are waiting for Food and Drug Administration approval, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). This latest PhRMA report on new, cutting-edge medicines in the research pipeline comes as a growing number of older Americans face severe health challenges and greater life expectancy.
Source: www.medicalnewstoday.com

Duska Therapeutics Applies For Phase 3 Special Protocol Assessment
Duska Therapeutics, Inc., (OTC Bulletin Board: DSKA), announced that it has submitted its pivotal Phase 3 ATPace clinical trial protocol for review under a Special Protocol Assessment (SPA) procedure with the U.S. Food and Drug Administration (FDA). Subject to securing an agreement with the FDA, Duska intends to initiate a single, prospective, double-blind, placebo-controlled and randomized Phase 3 clinical trial with its lead product ATPace.
Source: www.medicalnewstoday.com